ALMS acquires SLRN for $2.35/sh* in stock—a 24% premium to today’s 4:00pm closing price: https://www.globenewswire.com/news-release/2025/02/06/3022460/0/en/Alumis-and-ACELYRIN-to-Merge-Creating-a-Late-Stage-Clinical-Biopharma-Company-Dedicated-to-Innovating-Developing-and-Commercializing-Transformative-Therapies-for-Immune-mediated-Di.html *Based on SLRN’s AH price of $5.51 (as I’m typing). The exchange ratio is 0.4274 shares of ALMS for each share of SLRN.